表紙
市場調査レポート

トルコのライフサイエンス市場の見通し

2014 Life Sciences Outlook in Turkey

発行 Frost & Sullivan 商品コード 318503
出版日 ページ情報 英文 108 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
トルコのライフサイエンス市場の見通し 2014 Life Sciences Outlook in Turkey
出版日: 2014年11月04日 ページ情報: 英文 108 Pages
概要

トルコの医薬品セグメントは、2013年に140億4,000万ドルに達し、世界第14位、欧州第6位の市場となりました。2013年〜2018年のCAGRでは、9.1%の成長が見込まれています。

当レポートでは、トルコのライフサイエンス(生命科学)市場について調査分析し、M&A/投資動向、規制環境、収益予測、主要動向、注目すべき企業などについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲と市場概要

  • 調査範囲
  • 市場区分
  • 市場概要
  • 状況
  • 3大成長部門
  • 主要動向
  • 注目すべき多国籍機魚う
  • 注目すべき国内企業
  • 医療ツーリズム市場
  • 戦略的行動計画

第3章 トルコの製薬業界のマクロ経済概要

  • 急成長する経済
  • 製薬業界の歴史
  • 概要
  • 主な改革
  • 戦略的計画
  • 影響
  • インフラの地域開発

第4章 人口統計と疾病負担

  • 高齢化
  • 若年労働力と雇用
  • 主な健康指標と死因
  • 主な疾病の罹患率
  • 主な感染症の発生率
  • がんの発生率

第5章 トルコの医薬品セグメントの分析

  • 分析
  • 収益予測
  • 収益率予測
  • 成長機会
  • 課題
  • SWOT分析

第6章 M&Aと投資動向

第7章 政府の取り組みによる研究開発と技術革新

第8章 医薬品セグメントのバリューチェーン

第9章 規制環境

  • 主な規制当局
  • SSI(SGK)
  • 価格規制
  • 償還規制
  • ライセンス手続
  • ライセンス規制

第10章 トルコの臨床診断セグメントの分析

  • 分析
  • 収益予測
  • 収益予測(サブセグメント別)
  • 成長機会
  • 課題

第11章 地域資本としてのトルコの台頭:政府のビジョン

  • 発展途上の地域資本
  • 自由貿易圏
  • MoHの戦略的計画
  • 科学産業技術省
  • 政府のビジョン
  • まとめ:3大予測
  • 免責事項

第12章 Frost & Sullivanについて

目次
Product Code: MA8D-01-00-00-00

Rapid Economic Development and Healthcare Reforms Set the Stage for the Future

The Turkish pharmaceuticals segment is the 14th largest worldwide and the 6th largest in Europe, valued at $14.04 billion in 2013 and projected to grow at a CAGR of 9.1% from 2013 to 2018. Growth is driven by expanding public insurance, modernisation, prevalence of chronic diseases, increasing health awareness, and affluence. Market segmentation is based on products (e.g., over-the-counter, generic, and patented drugs) and therapeutic areas (e.g., antibiotics, anti-rheumatics, cardiovascular, analgesics, oncology, cough preparations, and central nervous system). The study provides a macroeconomic overview of Turkey's mergers and acquisitions/investment trends, regulatory environment, revenue forecasts, key trends, and companies to watch.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Executive Summary
  • 2. Executive Summary (continued)

2. STUDY SCOPE AND MARKET OVERVIEW

  • 1. Study Scope
  • 2. Study Scope-Segmentation of the Pharmaceutical Industry
  • 3. Study Scope-Segmentation of Pharmaceutical Industry (continued)
  • 4. Study Scope-Segmentation of Pharmaceutical Industry (continued)
  • 5. Total Life Sciences Market-Segmentation
  • 6. Turkey Life Sciences Market-Snapshot
  • 7. State of Turkey Life Sciences in 2012 and 2013
  • 8. Top 3 Growth Sectors
  • 9. Accelerating Trends Make Their Mark in Turkey
  • 10. MNCs to Watch-High Tech, M&A, and Value-based Products to Capitalize on First-mover Advantage
  • 11. Domestic Companies to Watch-Pioneers of R&D Paving the Way for Innovation in Turkey
  • 12. Medical Tourism Market-Still Attractive
  • 13. Strategic Action Plan for the Pharmaceuticals Segment- Current Ranking and Vision 2023

3. MACROECONOMIC OVERVIEW OF THE TURKISH PHARMACEUTICAL INDUSTRY

  • 1. Turkey-A Rapid-growing Economy
  • 2. History of the Turkish Pharmaceutical Industry
  • 3. HTP-Overview
  • 4. HTP-Major Reforms 2003 to 2010
  • 5. HTP-Strategic Plan 2010 to 2014
  • 6. Impact of the HTP-Universal Health Insurance
  • 7. Impact of the HTP-FP Services
  • 8. Impact of the HTP-Management of Diseases and Promotion of Health
  • 9. HTP-Regional Development of Infrastructure
  • 10. Impact of the HTP-Development of Health Infrastructure
  • 11. Impact of the HTP-Increased Healthcare Spending
  • 12. Impact of the HTP-Increased Healthcare Spending (continued)
  • 13. Impact of the HTP-Increased Pharmaceutical Spending
  • 14. Impact of the HTP-Tapering Out-of-pocket Payment

4. DEMOGRAPHICS AND DISEASE BURDEN

  • 1. Demographics-Aging Population
  • 2. Demographics-Young Workforce and Employment
  • 3. Demographics-Key Health Indicators and Top Causes of Death
  • 4. Disease Burden-Prevalence Rates of Top Diseases
  • 5. Disease Burden-Incidences of Top Infectious Diseases
  • 6. Disease Burden-Cancer Incidence Rates

5. ANALYSIS OF THE TURKISH PHARMACEUTICALS SEGMENT

  • 1. Pharmaceuticals Segment Analysis
  • 2. Pharmaceuticals Segment-Revenue Forecast
  • 3. Pharmaceuticals Segment-Percent Revenue Forecast by Product
  • 4. Pharmaceuticals Segment-Percent Revenue Forecast by Therapeutic Area
  • 5. Growth Opportunities in the Pharmaceuticals Segment
  • 6. Challenges in the Pharmaceuticals Segment
  • 7. Pharmaceuticals Segment-SWOT Analysis

6. MERGERS AND ACQUISITIONS AND INVESTMENT TRENDS-ARE YOU PUTTING YOUR MONEY IN THE RIGHT MARKET

  • 1. Turkey-A Lucrative Hub for Foreign Investors
  • 2. Big Pharma Heavy Investment Plans in Turkey
  • 3. M&A Activity Intensifies in Turkey
  • 4. M&A Activity Intensifies in Turkey (continued)

7. GOVERNMENT INITIATIVES TO FOSTER RESEARCH AND DEVELOPMENT AND INNOVATION

  • 1. Turkey Clinical Research Attractiveness Index
  • 2. Incentive Programs to Foster R&D and Innovation in Turkey
  • 3. R&D Incentive Programs-TUBITAK-TEYDEB
  • 4. R&D Incentive Programs-TDZ
  • 5. R&D Incentive Programs-SAN-TEZSAN-TEZ
  • 6. Key Research Centres Active in Pharmaceutical R&D
  • 7. Key International Companies Active in Pharmaceutical R&D
  • 8. Key International Companies Active in Pharmaceutical R&D (continued)
  • 9. Key Local Companies Active in Pharmaceutical R&D

8. PHARMACEUTICALS SEGMENT VALUE CHAIN-KEY STAKEHOLDERS INFLUENCING PRODUCTION AND SALES

  • 1. Pharmaceutical Production-Export-Import Ratio
  • 2. Pharmaceutical Raw Materials Production-Key Stakeholders
  • 3. Pharmaceutical Raw Materials Production-Key Stakeholders (continued)
  • 4. Pharmaceutical Raw Materials Production-Key Stakeholders (continued)
  • 5. Pharmaceutical Production Capacity Utilisation
  • 6. Top 10 Pharmaceutical Companies in Turkey
  • 7. Pharmaceutical Production-Key Stakeholders
  • 8. Pharmaceutical Wholesale Market-Turkey
  • 9. Pharmaceutical Wholesale Market-Key Stakeholders
  • 10. Pharmaceutical Retail Market-Turkey

9. REGULATORY ENVIRONMENT-AN INTEGRAL PART OF ANY HEALTHCARE CONVERSATION

  • 1. Key Regulatory Bodies that Govern the Turkish Pharmaceutical Industry
  • 2. Key Regulatory Bodies that Govern the Turkish Pharmaceutical Industry (continued)
  • 3. Key Regulatory Bodies that Govern the Turkish Pharmaceutical Industry (continued)
  • 4. Turkey's SSI (SGK) Healthcare Coverage
  • 5. Pharmaceutical Pricing Regulation in Turkey
  • 6. Pharmaceutical Reimbursement Regulation in Turkey
  • 7. Pharmaceuticals Segment-Reimbursements in Turkey
  • 8. Pharmaceutical Licensing Procedure in Turkey
  • 9. Pharmaceutical Licensing Regulation

10. ANALYSIS OF THE TURKISH CLINICAL DIAGNOSTICS SEGMENT

  • 1. Clinical Diagnostics Segment Analysis
  • 2. Clinical Diagnostics Segment-Revenue Forecast
  • 3. Clinical Diagnostics Segment-Revenue Forecast by Sub-segment
  • 4. Growth Opportunities in the Clinical Diagnostics Segment
  • 5. Challenges in the Clinical Diagnostics Segment

11. TURKEY TO EMERGE AS THE REGIONAL (MENA) LIFE SCIENCES CAPITAL-GOVERNMENT'S VISION 2023

  • 1. Turkey-A Developing Regional Life Sciences Capital
  • 2. Free Healthcare Zones-A Strategic Initiative Propelled by the Growing Medical Tourism Industry in Turkey
  • 3. MoH-Strategic Plan 2013 to 2017: Improvement of Public Health
  • 4. Ministry of Science, Industry, and Technology-Strategic Goals
  • 5. The Government's 2023 Vision
  • 6. The Last Word-3 Big Predictions
  • 7. Legal Disclaimer

12. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top